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T h e  n e w  e ngl a nd  j o u r na l  o f  m e dic i n e
c o r r e s p o n d e n c e
Timing of Antiretroviral Therapy for HIV-1–Associated 
Tuberculosis
To the Editor: Three randomized trials report-
ed by Blanc et al.,1 Havlir et al.,2 and Abdool 
Karim et al.3 (Oct. 20 issue) consolidate the evi-
dence base underpinning recommendations on 
when to start antiretroviral therapy (ART) in pa-
tients with human immunodeficiency virus 
(HIV)–associated tuberculosis. However, more 
than 80% of the global burden of this disease is 
in sub-Saharan Africa, where the health care in-
frastructure is weak and a lack of integration of 
the health care pathway represents a major hur-
dle to timely initiation of ART.4 Patients typically 
attend completely separate HIV and tuberculosis 
clinics in different localities. In a township in 
South Africa, we found that delays in starting 
ART were almost three times as high in patients 
who were referred between nonintegrated tuber-
culosis services and ART clinics as in those with 
tuberculosis that was diagnosed in the ART clin-
ic.5 Thus, among patients with CD4 counts of 
less than 50 cells per cubic millimeter who were 
referred to tuberculosis clinics, only 11% started 
ART within 4 weeks after receiving a diagnosis of 
tuberculosis. This is a prime example of how a 
lack of integration of tuberculosis and ART ser-
vices compromises patient care. Progress toward 
integration is slow and must be accelerated. The 
time between tuberculosis diagnosis and initia-
tion of ART might be a useful indicator of suc-
cessful integration.
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To the Editor: Török and Farrar1 summarize 
the findings of three controlled trials of when to 
start ART in HIV-associated tuberculosis and 
raise a number of practical issues to consider 
outside of the research setting. A practical point 
not considered is the setting of ART initiation. 
Loss to follow-up is typically the largest contrib-
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utor to attrition from HIV care,2 and initiating 
ART in patients in the hospital is associated with 
a doubling of the risk of loss to follow-up as 
compared with initiating ART in patients who 
are not in the hospital.3
Inpatient ART initiation will be necessary in 
severely immunocompromised patients or those 
with long hospital stays, in which case adequate 
linkage to community programs must be en-
sured. Studies show that ART can safely be de-
layed in less severely immunocompromised pa-
tients with the possible advantages of reduced 
risks of immune reconstitution inflammatory 
syndrome (IRIS) and adverse events leading to 
switches in antiretroviral drugs.
Outpatient ART initiation should be the pre-
ferred option whenever possible. Adequate link-
age to outpatient care allowing prompt ART 
initiation in the community will also be impor-
tant in securing the success of this approach.
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Dr. Blanc and coauthors Reply: Lawn and 
Wood point out that a major hurdle to rapidly 
initiating ART in patients with HIV-associated 
tuberculosis is the separation between tubercu-
losis and HIV services that is typical of most re-
source-limited settings. We cannot agree more. 
On the basis of the results of the Cambodian 
Early versus Late Introduction of Antiretrovirals 
trial (CAMELIA; ClinicalTrials.gov number, 
NCT00226434) and two other recent studies, 
which show that early initiation of ART in very 
immunosuppressed patients with tuberculosis 
decreases mortality, it is no longer acceptable to 
allow patients to wait for treatment while being 
referred from tuberculosis services to HIV ser-
vices or vice versa. In these patients, tuberculosis 
treatment and ART should be initiated at the 
same place to save time and to ultimately save 
lives. Therefore, to reduce the interval between 
the start of treatment for each of the two infec-
tions, we urge early initiation of ART in tubercu-
losis services and an expedited process for pa-
tients to receive tuberculosis treatment in HIV 
services. We anticipate that this strategy, which 
was successfully accomplished in Cambodia dur-
ing the CAMELIA trial, will have a considerable 
impact on the mortality associated with tubercu-
losis and HIV coinfection.
François-Xavier Blanc, M.D., Ph.D.
Bicêtre Hospital 
Le Kremlin-Bicêtre, France 
xavier.blanc@bct.aphp.fr
Didier Laureillard, M.D.
Agence Nationale de Recherche sur le Sida et les Hépatites Virales 
Ho Chi Minh City, Vietnam
Anne E. Goldfeld, M.D.
Harvard Medical School 
Boston, MA
Since publication of their article, the authors report no fur-
ther potential conflict of interest.
Dr. Havlir and coauthors Reply: Delivering 
antiretroviral therapy as early as 2 weeks after a 
tuberculosis diagnosis will require major adapta-
tions in health delivery for patients with HIV and 
tuberculosis. As reported by Lawn and Wood, in-
adequate integration of HIV and tuberculosis 
services leads to delays in antiretroviral initiation 
and excess mortality.1 Several models to deliver 
integrated care are emerging and include “partial 
integration,” in which tuberculosis clinics man-
age antiretroviral therapy during tuberculosis 
treatment and “co-location” of HIV and tubercu-
losis clinics. With any model, streamlined HIV 
counseling, provider education including man-
agement of the IRIS, and rigorous infection-con-
trol policies to reduce transmission of tuberculo-
sis are essential components.2 Integration of 
some HIV and tuberculosis activities such as HIV 
testing among tuberculosis patients has in-
creased over the past few years.3 New data from 
our study and others call for acceleration of the 
integration of HIV and tuberculosis services and 
early delivery of HIV antiretroviral therapy to re-
duce mortality and AIDS among HIV-infected 
patients who acquire tuberculosis.
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The Editorialists Reply: The health care set-
ting in which ART is initiated is one of the fac-
tors associated with successful care of patients 
with HIV-associated tuberculosis. However, such 
decisions need to take into account the patient, 
his or her community, the clinical facilities avail-
able, and the extent to which tuberculosis and 
HIV care is integrated. The recent studies sug-
gest that early ART initiation is beneficial in pa-
tients with opportunistic infections and ad-
vanced immunosuppression, with the exception 
of those with central nervous system infections. 
In patients with severe or life-threatening HIV-
related illnesses, initiation of ART in the inpa-
tient setting is clearly prudent. For patients who 
are not hospitalized, outpatient initiation of ART 
is preferable. Even in the outpatient setting, how-
ever, delays in the initiation of ART1 and loss to 
follow-up2,3 are common. Loss to follow-up may 
result from poor coordination of HIV and tuber-
culosis services, rather than simply being a con-
sequence of where the ART was initiated. The key 
to improving outcomes for patients with HIV-
associated tuberculosis is coordinated and inte-
grated HIV and tuberculosis services.4 How that 
is achieved requires a locally relevant, flexible, 
and pragmatic approach.
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Glucocorticoids plus N-Acetylcysteine in Alcoholic Hepatitis
To the Editor: The study by Nguyen-Khac et al. 
(Nov. 10 issue)1 sidesteps old contentious issues 
regarding the use of glucocorticoid therapy in al-
coholic hepatitis. Among the 8 references cited 
in support of glucocorticoid treatment, 2 in fact 
concluded that the therapy was of no benefit.2,3 
In addition, 8 of 13 clinical trials published since 
1971 showed that glucocorticoid therapy had no 
benefit as compared with placebo, although 5 of 
these did suggest an association with decreased 
short-term mortality.
The rationale for treating alcoholic hepatitis 
with antiinflammatory agents is soft. It is illogi-
cal to inhibit cytokines instead of targeting the 
putative pathogens that induce them. Exposing 
immunocompromised patients with severe alco-
holic hepatitis to high-dose steroids exacerbates 
their already increased risk of infection, and the 
benefits are far from proven. In a multicenter 
trial of prednisolone and infliximab in the treat-
ment of severe alcoholic hepatitis, increased 
mortality in the infliximab group caused prema-
ture termination of the study.4
In the study by Nguyen-Khac et al., N-acetyl-
cysteine was associated with fewer infectious 
complications, but the primary outcome was not 
improved. The idea of adding one unproven 
treatment to another has little merit.
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